Trial Design: A single arm, phase II, multicentre trial of intramuscular triamcinolone administered monthly in metastatic castration resistant prostate cancer (CRPR). Triamcinolone has putative advantages over commonly used steroids, including lack of weight gain and an inability to stimulate mutated androgen receptors. 55 patients were recruited over 2012-2016 and imaging was performed every 3 months. The primary end point was radiological and symptomatic progression-free survival (PFS). Secondary end points included PSA progression, weight changes and toxicity. Steroid androgenic precursors, cortisol and circulating tumour cells were assessed prior to and 1 month after triamcinolone to see if they correlated with PFS.
A Phase II Trial of Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST) in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer. K. Ng, S.-J. Sarker, M. Greenwood et al. Clinical Oncology 31, 2, E23-E24, February 01, 2019.
Cancer Research UK website A trial of triamcinolone with hormone therapy for prostate cancer (TRICREST)